- Details
- Alicia Morgans joins Oliver Sartor in this UroToday conversation highlighting a modeling analysis of cabazitaxel compared to repeat treatment with an androgen receptor targeting agent (ARTA) among patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA. This analysis uses a hypothetical cohort of patients who are similar to t...
|
- Details
- Neeraj Agarwal joins Alicia Morgans for a conversation on the TALAPRO-3 data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting. The TALAPRO-3 trial is a phase 3 trial assessing enzalutamide plus talazoparib versus placebo plus enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC). They discuss how this trial fits into the l...
|
- Details
- Guru Sonpavde joins Ashish Kamat sharing takeaways from the 2021 ESMO meeting starting with practice-changing or practice reaffirming studies, followed by other emerging drugs and data. Dr. Sonpavde highlighted the landmark phase 3 EV-301 study that led to the approval of enfortumab vedotin in post-platinum and PD-1 inhibitor-treated patients with metastatic urothelial carcinoma. Among the other s...
|
- Details
- Alicia Morgans and Eugene Shenderov, discuss Dr Shenderov’s recent ESMO 2021 presentation on MGCO18, an anti-B7-H3 antibody-drug conjugate. Dr. Shenderov presented preliminary results of a phase one cohort expansion, testing MGC018, an investigational ADC with a duocarmycin payload linked to an anti-B7-H3 monoclonal antibody, in patients with metastatic castration-resistant prostate cancer (mCRPC)...
|
- Details
- During the European Society for Medical Oncology (ESMO) Annual Congress, Wassim Abida presented an analysis of the safety and efficacy of tazemetostat in combination with abiraterone/prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). In this UroToday discussion, Dr. Abida joins Alicia Morgans to provide a background of the study and to share the re...
|
- Details
- Alicia Morgans and Giulia Baciarello, discuss the CABA-GCT Study, an academic trial looking at cabazitaxel in patients with refractory germ cell tumors. Biographies: Giulia Baciarello, MD, Medical Oncology 1, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Ca...
|
- Details
- Elena Castro joins Alicia Morgans to discuss the PRORADIUM study, examining the effect of germline mutations on outcomes for patients treated with radium-223. The hypothesis of this study was that patients with germline mutations in HR genes may have a potentiated response to radium-223. Regulatory approved based on data from the ALSYMPCA trial, radium-223 is an alpha-emitter that induces double-s...
|
- Details
- In this UroToday discussion, Daniel Petrylak joins Tom Keane highlighting the ESMO 2021 data on CheckMate 9KD cohort A2. This was the final analysis of nivolumab and rucaparib for chemotherapy- naïve metastatic castration-resistant prostate cancer. Biographies: Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology; Co-Leader, Cancer Signaling Networks, Yale Cancer Center,...
|
- Details
- In this conversation with Alicia Morgans, Matthew Galsky highlights an exploratory analysis within the IMvigor130 randomized phase III study of patients with metastatic urothelial cancer who were treatment-naive. IMvigor130 was asking two separate questions, should we combine platinum-based chemotherapy with atezolizumab versus giving platinum-based chemotherapy alone, and should we give immune ch...
|
- Details
- In this UroToday discussion between Alicia Morgans and Mark Markowski, they discuss the results of a Phase 1b/2 study of sabizabulin, an androgen receptor transport disruptor, in men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent. Sabizabulin is an oral agent that inhibits microtubule assembly as well as disrupts androgen receptor trans...
|
